About this Series

Over the past decade, a dramatically new treatment landscape has emerged for the care of patients with advanced-stage melanoma. Since 2010, the US Food and Drug Administration has approved more than 10 drugs, including immunotherapies, molecularly targeted therapies, and numerous combination therapies.

With the durable benefit provided by these new agents, evidence shows that as many as 50% of patients with metastatic disease are now living more than 3 years, and some as long as 8 years, without recurrence, after multiple therapies. Not so just 10 years ago, when no medications were shown to improve overall survival in melanoma. Still, experts report, a third of patients with metastatic melanoma remain refractory to treatment.

In this series, University of Chicago oncologists and immunology experts work to increase patient survival with the use of the latest therapies as well as new modalities in clinical trials. Their immune response research, particularly in the area of gut microbiota, may soon offer up clues to prevent melanoma cells from becoming resistant to immunotherapy and may identify potential new biomarkers of immune response.

Show More

Who's Who
More on Metastatic Melanoma